Abstract
The physical characteristics and lipoprotein distribution of free nystatin (NYS) and liposomal NYS (L-NYS) in human plasma were investigated. To determine the percentage of NYS that was lipid associated following incubation in human plasma, C18 reverse-phase extraction columns were used. To assess plasma drug distribution, NYS and L-NYS (20 microg/ml) were incubated in human plasma for 5, 60, and 120 min at 37 degrees C. After each interval, plasma was removed and separated into its lipoprotein and lipoprotein-deficient plasma (LPDP) fractions by ultracentrifugation and assayed for NYS by high-pressure liquid chromatography. Further studies evaluated the liposome structure of L-NYS by filtering through a 0.14-microm-pore-size microfilter before and after the addition of human plasma. When reconstituted L-NYS (mean particle diameter +/- standard deviation, 321 +/- 192 nm) was applied to a C18 column, 67% +/- 4% of the initial NYS concentration was associated with the lipid. When plasma samples containing L-NYS that had been incubated for 5 to 120 min at 37 degrees C were applied to C18 columns, 66 to 76% of the NYS was lipid associated. Incubation of NYS in human plasma for 5 min at 37 degrees C resulted in 3% +/- 1% of the initial NYS concentration incubated in the low-density lipoprotein (LDL) fraction, 23% +/- 4% of that in the high-density lipoprotein (HDL) fraction, and 66% +/- 10% of that in the LPDP fraction. In contrast, the distribution of NYS following incubation of L-NYS in human plasma for 5 min was 13% +/- 2% in the LDL fraction, 44% +/- 5% in the HDL fraction, and 42% +/- 5% in the LPDP fraction. Similar results were observed following 60 and 120 min of incubation. In addition, the liposome structure of L-NYS was quickly lost when mixed with plasma. These findings suggest that rapid disruption of the L-NYS structure upon incubation in human plasma is consistent with its rapid distribution in plasma. The preferential distribution of NYS into the HDL fraction upon incubation of L-NYS may be a function of its phospholipid composition.
Full Text
The Full Text of this article is available as a PDF (187.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dhondt F., Ninane J., De Beule K., Dhondt A., Cauwenbergh G. Oral candidosis: treatment with absorbable and non-absorbable antifungal agents in children. Mycoses. 1992 Jan-Feb;35(1-2):1–8. doi: 10.1111/j.1439-0507.1992.tb00812.x. [DOI] [PubMed] [Google Scholar]
- HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koldin M. H., Kobayashi G. S., Brajtburg J., Medoff G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother. 1985 Jul;28(1):144–145. doi: 10.1128/aac.28.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krieger M. The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal Biochem. 1983 Dec;135(2):383–391. doi: 10.1016/0003-2697(83)90700-5. [DOI] [PubMed] [Google Scholar]
- Lopez-Berestein G., Rosenblum M. G., Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1984 Summer;1(3):199–205. doi: 10.1089/cdd.1984.1.199. [DOI] [PubMed] [Google Scholar]
- Medoff G., Brajtburg J., Kobayashi G. S., Bolard J. Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol. 1983;23:303–330. doi: 10.1146/annurev.pa.23.040183.001511. [DOI] [PubMed] [Google Scholar]
- Mehta R. T., Hopfer R. L., Gunner L. A., Juliano R. L., Lopez-Berestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 1987 Dec;31(12):1897–1900. doi: 10.1128/aac.31.12.1897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schaffner C. P., Mechlinski W. Polyene macrolide derivatives. II. Physical-chemical properties of polyene macrolide esters and their water soluble salts. J Antibiot (Tokyo) 1972 Apr;25(4):259–260. [PubMed] [Google Scholar]
- Selvam M. P., Blay R. A., Geyer S., Buck S. M., Pollock L., Mayner R. E., Epstein J. S. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents. AIDS Res Hum Retroviruses. 1993 May;9(5):475–481. doi: 10.1089/aid.1993.9.475. [DOI] [PubMed] [Google Scholar]
- Stevens N. M., Engle C. G., Fisher P. B., Mechlinski W., Schaffner C. P. In vitro antiherpetic activity of water-soluble amphotericin B methyl ester. Arch Virol. 1975;48(4):391–394. doi: 10.1007/BF01317438. [DOI] [PubMed] [Google Scholar]
- Thies R. L., Cowens D. W., Cullis P. R., Bally M. B., Mayer L. D. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem. 1990 Jul;188(1):65–71. doi: 10.1016/0003-2697(90)90528-h. [DOI] [PubMed] [Google Scholar]
- Wasan E. K., Reimer D. L., Bally M. B. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci. 1996 Apr;85(4):427–433. doi: 10.1021/js9504752. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Brazeau G. A., Keyhani A., Hayman A. C., Lopez-Berestein G. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother. 1993 Feb;37(2):246–250. doi: 10.1128/aac.37.2.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wasan K. M., Conklin J. S. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin Infect Dis. 1997 Jan;24(1):78–80. doi: 10.1093/clinids/24.1.78. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis. 1996 Nov;23(5):1126–1138. doi: 10.1093/clinids/23.5.1126. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Lopez-Berestein G. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res. 1993 Winter;24(4):395–401. [PubMed] [Google Scholar]
- Wasan K. M., Morton R. E. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm Res. 1996 Mar;13(3):462–468. doi: 10.1023/a:1016065114515. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Morton R. E., Rosenblum M. G., Lopez-Berestein G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994 Jul;83(7):1006–1010. doi: 10.1002/jps.2600830716. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Perez-Soler R. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J Pharm Sci. 1995 Sep;84(9):1094–1100. doi: 10.1002/jps.2600840912. [DOI] [PubMed] [Google Scholar]
- Wasan K. M., Rosenblum M. G., Cheung L., Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother. 1994 Feb;38(2):223–227. doi: 10.1128/aac.38.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wasan K. M., Vadiei K., Lopez-Berestein G., Luke D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar;161(3):562–566. doi: 10.1093/infdis/161.3.562. [DOI] [PubMed] [Google Scholar]